Key facts
- Hilltop Leaf’s last known valuation is $32.7M (Jan 2025).
- It has raised $11.2M; the latest was Later Stage VC ($6.3M) in Jan 2025.
- Notable investors include South of Scotland Enterprise, Traditum.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Hilltop Leaf
- ·The full record, as it builds
Funding rounds
No funding rounds for Hilltop Leaf are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hilltop Leaf
Operator of a medicinal cannabis cultivation and extraction company intended to produce a cannabis-based medicinal product (CBMP). The company primarily provides drugs in the form of cannabinoid oils, Active Pharmaceutical Ingredients (API), and other cannabis-based medical products, enabling patients with treatment for a range of conditions from chronic pain to severe epilepsy.
- Sector
- Materials and Resources
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 10
- Website
- hilltopleaf.com/
- Ownership
- Privately Held (backing)
Hilltop Leaf doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hilltop Leaf shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hilltop Leaf in its N-PORT filings yet. We sweep new filings monthly.